Full Text View
Tabular View
No Study Results Posted
Related Studies
Role of Genetic Factors in the Development of Lung Disease
This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), February 2009
First Received: November 3, 1999   Last Updated: November 25, 2009   History of Changes
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00001532
  Purpose

This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease.

The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers.


Condition
Cystic Fibrosis
Sarcoidosis
Tuberous Sclerosis
Asthma

Study Type: Observational
Official Title: Role of Genetic Factors in the Pathogenesis of Lung Disease

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 2500
Study Start Date: June 1996
Detailed Description:

This study is designed to evaluate genetic mechanisms of lung disease by surveying polymorphic genes involved in respiratory function and examining gene expression in the lung cells of individuals with pulmonary disease (e.g., alpha 1-antitrypsin deficiency, asthma, chronic obstructive pulmonary disease, cystic fibrosis, sarcoidosis, history of infection, and genetic mutations consistent with lung pathology). Emphasis will be on defining the distribution of allelic variants of nitric oxide synthase, alpha 1-antitrypsin, and the cystic fibrosis transmembrane conductance regulator genes in patients and in age- and sex-matched healthy individuals in a control population.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

Inclusion criteria for patients with AAT deficiency include: (1) Diagnosis of AAT with a confirmed phenotype considered in the high risk category; (2) Clinical phenotype consistent with potential genetic diseases and other genetic causes of lung diseases (3) symptoms consistent with pulmonary disease; (4) chest x-ray consistent with pulmonary disease; (5) pulmonary function tests consistent with pulmonary disease; (6) smokers, defined as individuals who are current smokers (1 pack per day for at least 2 years) and nonsmokers, defined as never-smokers or ex-smokers who have quit smoking three or more years ago;

Inclusion criteria for individuals with chronic obstructive pulmonary diseases include:

  1. symptoms consistent with pulmonary disease
  2. chest x-ray consistent with pulmonary disease
  3. pulmonary function tests consistent with pulmonary disease;
  4. smokers, defined as individuals who are current smokers (1 pack per day for at least 2 years) and nonsmokers, defined as never-smokers or ex-smokers who have not smoked for three or more years.

Inclusion criteria for patients with cystic fibrosis include a defined genetic mutation (i.e., any of the known variants of the CFTR gene, such as delta F508 allele) or a cystic fibrosis phenotype and clinical features consistent with this disease. Children with cystic fibrosis over eight years of age may be included.

Patients with established diagnoses of sarcoidosis; mycobacterial infections; TSC; cystic lung disease including genetic diseases; lymphangioleiomyomatosis or diseases associated with lymphatic disorders; history of pneumothorax; pulmonary fibrosis; asthma; histiocytosis X and diabetes mellitus will be included in this protocol.

Research volunteers in the pulmonary control group are defined as individuals with no pulmonary disease (e.g. rheumatoid arthritis without evidence of pulmonary disease). Research volunteers in the diabetes control group are defined as individuals with no history of diabetes, coronary artery disease, or pulmonary disease.

Because radiation exposure is not required, pregnant women are not excluded from the study.

EXCLUSION CRITERIA:

Exclusion criteria for all participants include:

  1. age less than 18 or greater than 80 except for patients with cystic fibrosis or unless patient-specific IRB approval is obtained and
  2. inability to obtain reliable pulmonary function testing.

Exclusion criteria for participating in the x-ray portion of the study is pregnancy.

Exclusion criteria for participating in the bronchoscopy portion of the study are:

  1. presence of any contraindication for fiberoptic bronchoscopy, with lavage and/or bronchial brushing
  2. advanced stage of a pulmonary or a systemic illness such that the risk is judged to be significant even in the absence of a specific contraindication to the procedure
  3. allergy to topical anesthetic (e.g., lidocaine)
  4. current or recent respiratory infection (within the last 4 weeks)
  5. pregnancy or lactation
  6. age less than 18 or greater than 65.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00001532

Contacts
Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 prpl@mail.cc.nih.gov
Contact: TTY 1-866-411-1010

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Suburban Hospital Recruiting
Bethesda, Maryland, United States, 20814
Sponsors and Collaborators
  More Information

Additional Information:
Publications:
Study ID Numbers: 960100, 96-H-0100
Study First Received: November 3, 1999
Last Updated: November 25, 2009
ClinicalTrials.gov Identifier: NCT00001532     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Genetic Polymorphism
Nitric Oxide Synthase
Alpha 1-Antitrypsin
Candidate Genes
Lung Pathology
Asthma
Lung Disease
Cystic Fibrosis
Asthma

Additional relevant MeSH terms:
Bronchial Diseases
Fibrosis
Nervous System Malformations
Neurodegenerative Diseases
Hypersensitivity
Lung Diseases, Obstructive
Heredodegenerative Disorders, Nervous System
Tuberous Sclerosis
Pathologic Processes
Respiratory Tract Diseases
Infant, Newborn, Diseases
Congenital Abnormalities
Neurocutaneous Syndromes
Immune System Diseases
Nervous System Diseases
Asthma
Sclerosis
Sarcoidosis
Hamartoma
Lymphatic Diseases
Neoplasms
Digestive System Diseases
Cystic Fibrosis
Genetic Diseases, Inborn
Lung Diseases
Hypersensitivity, Immediate
Pancreatic Diseases
Lymphoproliferative Disorders
Malformations of Cortical Development
Respiratory Hypersensitivity

ClinicalTrials.gov processed this record on February 08, 2010